louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05029869: Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description
Official title: Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastric Cancer
ctDNA
Lead sponsor: University Medical Center Ho Chi Minh City (UMC)
Sponsor class: OTHER
First posted: 2021-09-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with newly diagnosed and untreated gastric adenocarcinoma

Brief summary: This study aims to evaluate the use of Next Generation Sequencing (NGS) to detect circulating tumor DNA in gastric cancer patients after gastrectomy

Detailed description: Gastric cancer is the fourth most common cancer in Vietnam with high mortality rate. Patients at early stages undergo radical gastrectomy with curative intent, but the remaining tumor cells, termed as minimal residual disease (MRD), can later cause relapse. Conventional methods to monitor MRD such as imaging and blood tests for biomarkers such as CEA are not sensitive and specific enough. ctDNA has recently emerged as a promising noninvasive marker with high accuracy to monitor MRD and detect relapse in many cancers such as breast and colorectal cancers. However, its application in gastric cancer has not been extensively evaluated. Therefore, this study aims to use advanced NGS technologies to detect ctDNA in liquid biopsy as a biomarker to monitor MRD after radical gastrectomy.

Eligibility criteria: Inclusion Criteria:

1. Male or Female patients aged 18 years and older
2. Histologically proven primary gastric adenocarcinoma before surgery
3. Clinical stage is locally advanced cT2-4a any N and M0
4. In initial evaluation, patient can undergo radical gastrectomy and lymphadenectomy
5. No preoperative therapy, including chemotherapy and radiotherapy
6. No known cancer diagnosis within last five years
7. Signed informed consent

Exclusion Criteria:

1. Gastrectomy cannot be achieved during operation due to metastasis
2. Patient fails to follow-up and provide postoperative samples

Primary outcomes:
measure: The sensitivity of MRD detection using ctDNA as the biomarker
timeFrame: 2 years after surgery
measure: The specificity of MRD detection using ctDNA as the biomarker
timeFrame: 2 years after surgery
Secondary outcomes:
measure: Leading time between ctDNA detection and cancer recurrence detected by conventional methods
timeFrame: 2 years after surgery
measure: Mean ctDNA level (MTM/ml) of gastric cancer before operation
timeFrame: Within 14 days before operation
measure: Mutation profile of gastric cancer
timeFrame: Within 14 days before operation
Other outcomes:
Locations:
city: Ho Chi Minh City
country: Vietnam
facility: University Medical Center Ho Chi Minh City
Study officials:
References:
Clinical trial NCT00344669: Effect of Mass Deworming on Child Growth
Official title: Increased Weight Gain in Preschool Children Due to Mass Albendazole Treatment Given During "Child Health Days" in Uganda
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Weight for Age in Preschool Children
Keywords: underweight
preschool
mass deworming
Lead sponsor: Makerere University
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Uganda
name: World Bank
First posted: 2006-06-27
Enrollment: 10000
Sex: ALL
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study was to determine whether periodical mass deworming improves growth in children below six years of age.

Detailed description: Many children in developing countries get slowed growth because of heavy loads of intestinal helminths. Quite often treatment is not sought because there may not be any obvious symptoms. Slowed growth may manifest as low weight for age or low height for age.

The objective of the study was to estimate the effectiveness of the delivery of an anthelmintic drug through a community child health program on the weight gain of preschool aged children.

Design: This was a cluster randomized controlled trial in 48 parishes in Eastern Uganda. All 48 parishes were participating in a new program for child health; 24 were randomly assigned to offer to children an additional service of anthelmintic treatment. The intervention was 400 mg of albendazole added to the standard services at child days over a 3 years period. All children were offered the drug and the main outcome measure was weight gain.

Results: A total of 27,995 children were recruited into the 2 arms of the study with 14,940 in the treatment arm and 13,055 in the control arm. The intervention arm got an increase in weight gain of about 10% (166 grams per child per year (CI: 16-316) above expected weight gain when treatment was taken twice a year and an increase of 5% when treatment was received approximately annually.

Conclusion: The inclusion of deworming in regularly scheduled health services appears practical and capable of increasing child growth.

Eligibility criteria: Inclusion Criteria:

* children 1-6 years

Exclusion Criteria:

-

Primary outcomes:
measure: weight gain
measure: weight for age
Secondary outcomes:
Other outcomes:
Locations:
city: Kampala
country: Uganda
facility: 48 parishes in Eastern Uganda
Study officials:
affiliation: Makerere University
name: Joseph K Konde-Lule, MD DPH MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Ministry of Health, Uganda
name: John F Mutumba, MBChB, MSc
role: STUDY_CHAIR
References:
Clinical trial NCT00061269: Videoendoscopic Drainage of Infected Pancreatic Collections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pancreatitis, Acute Necrotizing
Keywords: Infected pancreatic necrosis
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2003-05-23
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The VARD (Videoendoscopic Assisted Retroperitoneal Drainage) approach as treatment for necrotizing pancreatitis proposes an alternative to standard complicated open abdomen treatment methods.

This treatment involves making a small incision and looking inside the abdomen with a videoendoscope. A videoendoscope is an instrument with a small camera and light on the end. It also has an extension tool that the surgeon can use to clean out any dead and infected tissue in the abdomen.

This approach may reveal a treatment opportunity with faster recovery potential and shorter hospitalizations for patients with necrotizing pancreatitis.


Eligibility criteria: * Pancreatic necrosis or peripancreatic fluid collection following acute pancreatitis noted on CT scan
* Infected pancreatic necrosis or pancreatic abscess and determined by + FNA (gram stain or culture), as defined by the Atlanta Symposium
* Not neutropenic or pregnant
* No prior necrosectomy
* No pancreatic pseudocyst, either sterile or infected

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health Sciences University
state: Oregon
city: Portland
country: United States
facility: Veteran's Administration-Portland
state: Oregon
city: Seattle
country: United States
facility: Harborview Medical Center
state: Washington
city: Seattle
country: United States
facility: Veteran's Administration Puget Sound
state: Washington
city: Seattle
country: United States
facility: University of Washington
state: Washington
city: Toronto
country: Canada
facility: University of Toronto
state: Ontario
Study officials:
References:
Clinical trial NCT01296269: Effects of Intranasal Oxytocin and Vasopressin on Social Behavior
Official title: Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Keywords: social cognition
oxytocin
vasopressin
decision making
social decision making
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
Collaborators: name: Hebrew University of Jerusalem
First posted: 2011-02-15
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to investigate the role of a one-time intranasal administration of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and altruism in a healthy population of student controls.


Eligibility criteria: Inclusion Criteria:

* healthy controls

Exclusion Criteria:

* Past or present psychiatric, neurological, endocrinological or severe chronic medical illness.
* Use of medications or drugs that would interfere with study results. This includes steroids, medications for psychiatric symptoms like anxiety or depression, stimulants, and medications for high blood pressure. Participants will be asked to tell the investigators of any medications or drugs that they are taking. The investigators will consider the drug interactions with oxytocin and vasopressin prior to study, and participants will not be able to participate in the study if the drug interactions could be dangerous.
* history of drug or alcohol addiction
* Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women who are pregnant or nursing are excluded from this protocol. All females will have a pregnancy test performed no more than 24 hours before each drug administration and will not be able to participate if the pregnancy test is positive.

Primary outcomes:
measure: allocations of monetary units
timeFrame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo
Secondary outcomes:
measure: mood as measured via the visual analog scale
timeFrame: approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah University Medical Organization
Study officials:
affiliation: Hadassah University Medical Organization
name: David Mankuta, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03177369: Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
Official title: Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Teicoplanin-based Antimicrobial Therapy
Staphylococcus Aureus
Bone and Joint Infection
Keywords: Bone and joint infection
Staphylococcus aureus
Teicoplanin
Subcutaneous administration
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-06-06
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with bone and joint infection caused by S. aureus managed in the reference center for BJI in Lyon, between 2001 and 2011.

Brief summary: Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycopeptides use, especially in case of methicillin-resistance or betalactam intolerance. Teicoplanin may represent an alternative to vancomycin because of its acceptable bone penetration and possible subcutaneous administration. Various studies have shown that teicoplanin pharmacodynamic profile was superior compared to vancomycin regarding bone diffusion. Few studies have investigated the use of teicoplanin in BJI, particularly through subcutaneous administration.

The aim of this study assesses the efficacy and tolerance of teicoplanin in S. aureus BJI, especially focusing on subcutaneous use. This study is a retrospective single-center observational cohort study (2001 to 2011) including all consecutive patients managed at our institution receiving teicoplanin as part of S. aureus BJI treatment.


Eligibility criteria: Inclusion Criteria:

- Patients with bone and joint infection caused by S. aureus receiving teicoplanin (IV or SC) as part to treat the infection

Exclusion Criteria:

- Patients with diabetic foot- and decubitus ulcer-related BJI

Primary outcomes:
measure: Efficacy of teicoplanin in S.aureus bone and joint infection
timeFrame: 90 weeks
Secondary outcomes:
measure: Tolerance of teicoplanin in S.aureus bone and joint infection
timeFrame: 6 weeks
measure: Pharmacocinetiks characteristics : Cmin value
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon - Hopital de la Croix Rousse - Centre de reference des infection ostéo-articulaires de Lyon
Study officials:
References:
Clinical trial NCT02640469: Alcohol Versus Chlorhexidine With and Without Water
Official title: Efficacy of the Use of Alcohol-bases Solutions Versus Chlorhexidine With or Without Water for Hand Sanitation Prior to Surgical Procedure
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Infection
Keywords: chlorhexidine
sterility
sterile hands
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2015-12-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Currently at NYU institutions, providine-iodine and chlorhexidine medicated soaps are available as hand disinfection options. The purpose of this study is to determine the relative efficacy of traditional hand scrubs with chlorhexidine with or without rinsing with water after scrubbing is complete versus dry hand rubs with alcohol.

Detailed description: No current recommendations exist advocating the use of Providine-iodine or Chlorhexidine. Providine-iodine is safe and effective at reducing skin colonization with gram positive and negative bacteria, mycobacterium tuberculosis, fungi and viruses. Chlorhexidine similarly disrupts cellular membranes. It is bacteriocidal and bacteriostatic and has immediate and more lasting effect than iodine because it can bind to the stratum corneum of the skin and is effective against gram positive and negative organisms, lipophilic viruses and yeasts.

All subjects who are employees of the NYU Hospital for Joint Diseases and have experience with surgical hand disinfection will be asked to enroll. Subjects will be randomized into one of three study arms using an online randomizer: (1) the standard chlorhexidine with water rinse, (2) chlorhexidine without water rinse(experimental), and (3) standard chlorhexidine followed by sterillium hand rub. After hand disinfection protocol has been completed, each subject will have each hand cultured three times using a cotton swab culture stick and sent to the microbiology lab for processing

Eligibility criteria: Inclusion Criteria:

* Orthopedic resident or surgical employee of NY U
* Over 21 years of age
* Procedural knowledge of correct aseptic scrub technique

Exclusion Criteria:

* No surgical experience
* Under 21 years of age
* Refusal to consent

Primary outcomes:
measure: Number of positive cultures in each group
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University Hospital for Joint Disease
state: New York
Study officials:
affiliation: NYU Langone Medical Center
name: Frank Liporace, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06010069: The Relationship Between the Frequency of Intraoperative Hypothermia and Fragility Scores
Official title: The Relationship Between the Frequency of Intraoperative Hypothermia and Fragility Scores in the Elderly Patient Group. Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypothermia; Anesthesia
Fragility
Lead sponsor: Kirsehir Ahi Evran Universitesi
Sponsor class: OTHER
First posted: 2023-08-24
Enrollment: 90
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Our candidates was choosen from patiens who scheduled for elective orthopedic surgeries in Kirsehir education and research hospital. We have enrolled patients who accepted to be a partician for this study after obtaining their informed consent. Elective Orthopedic Surgery. All of our participants were 65 years old or older.

Brief summary: The goal of this observational study is to compare frequency of intraoperative hypothermia between fragilitly groups of eldery patients who underwent orthopedic surgical procedures.

It aims to answer those questions:

* İs there any difference between fragility groups in terms of hypothermia frequency during orthopedic surgical procedures?
* Are there any other factors that influence the frequency of hypothermia such as age, body mass index, room temperature etc. ? Participants body temperature before anestesia application,and before surgery had started was measured and measurament was done during whole procedure. Measuraments had been done by tympanic thermometer.


Eligibility criteria: Inclusion Criteria:

* Elective Orthopedic Surgery Candidates
* 65 years old or older

Exclusion Criteria:

* Emergency surgery
* Patiens who required multiple (2 or more) blood component transfusions
* Neurologic disorders
* tyroid dysfunction
* Patiens who are already hypothermic before surgery

Primary outcomes:
measure: frequency of hypothermia
timeFrame: during the orthopedic surgical procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Kırşehir
country: Turkey
facility: Kırşehir Eğitim ve Araştırma Hastanesi
state: Merkez
Study officials:
References:
Clinical trial NCT00852969: Niacin and Endothelial Function in Early CKD
Official title: Does Raising HDL-C With Niacin Improve Endothelial Function in Early CKD?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Kidney Disease
Keywords: Chronic Kidney Disease
Niacin
HDL
Endothelial Function
Lead sponsor: Tufts Medical Center
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2009-02-27
Enrollment: 30
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to obtain information on whether raising levels of HDL-cholesterol (the "good" cholesterol) can improve how blood vessels work in kidney disease. This may help us understand the causes leading to high rates of heart disease in kidney disease and also ways to reduce this risk.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of CKD Stage 2 (GFR \>60 and microalbuminuria/proteinuria) and Stage 3-4 (GFR 15-30)
* HDL-cholesterol \<50 for men and \<55 for women
* If taking a statin, stable dose for past one month
* Glucose \<200 mg/dL and HbA1c \<9%
* Transplant recipients who are in stage 2-3 CKD; 1-year post transplant; and have had no rejection episodes in the 6-months prior to study entry

Exclusion Criteria:

* Hospitalization within prior 3 months
* Any of the following conditions:

  * uncontrolled peptic ulcer disease
  * active liver disease OR abnormal SGOT/SGPT
  * history of adverse reaction to niacin
  * contra-indication to aspirin
  * concurrent fibrate therapy
  * history of gout
  * serum phosphorus levels below 2.7mg/dl
* Nursing
* Pregnancy

Primary outcomes:
measure: Change in the Flow Mediated Dilation From Baseline
timeFrame: 14 weeks since baseline
Secondary outcomes:
measure: Change in HDL-C From Baseline to 14 Weeks
timeFrame: 14 weeks since baseline
Other outcomes:
Locations:
city: Boston
country: United States
facility: Tufts Medical Center
state: Massachusetts
Study officials:
affiliation: Tufts Medical Center
name: Mark Sarnak, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05992168: Stent-Retriever for Acute Massive Pulmonary Embolism (SRAME)
Official title: A Prospective, Multicenter, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Thrombectomy Devices for the Treatment of Acute Pulmonary Embolism
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: PE - Pulmonary Embolism
PE - Pulmonary Thromboembolism
Lead sponsor: Suzhou Zenith Vascular Scitech Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-08-15
Enrollment: 123
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate treatment outcomes of patients diagnosed with pulmonary embolism.


Eligibility criteria: Inclusion Criteria:

- 1.18≤ age ≤75, no gender limitation; 2.patients clinically diagnosed as acute pulmonary embolism requiring pulmonary artery thrombosis clearance; 3.RV/LV ratio ≥0.9; 4.Patients who agreed to participate in the study and voluntarily signed the informed consent.

Exclusion Criteria:

1. Patients with systolic blood pressure\<90 mmHg and lasting for 15 minutes or requiring maintenance of systolic blood pressure ≥ 90 mmHg;
2. Patients with known severe pulmonary hypertension;
3. Patients with Hematocrit \<28%;
4. Patients with known structural heart disease;
5. Patients with left bundle branch block;
6. Patients with history of chronic left heart failure and left ventricular ejection fraction ≤30%;
7. Patients with abnormal renal function (serum creatinine \> 1.8 mg/dL or \>159 umol/L);
8. Patients with known coagulopathy or bleeding tendency (platelet \<100×109/L, or INR\> 3);
9. Patients who cannot receive antiplatelet or anticoagulant therapy;
10. Patients who underwent cardiovascular or pulmonary open surgery within 7 days before peocedure;
11. Patients with intracardiac thrombosis;
12. Patients treated with extracorporeal membrane oxygenation;
13. Patients known to be allergic to contrast agents;
14. Patients with diseases that may cause difficulty in treatment or evaluation (such as malignant tumor, acute infectious disease, sepsis, general condition that cannot tolerate procedure, life expectancy less than one year, etc.);
15. Females who are pregnant or in lactation;
16. Patient is currently enrolled in another investigational study protocol;
17. Other conditions not suitable for inclusion judged by the researcher.

Primary outcomes:
measure: Reduction in RV/LV ratio from baseline to 48 hours
timeFrame: 48 hours post procedure
measure: Major Adverse Events from baseline to 48 hours
timeFrame: 48 hours post procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People'S Hospital
Study officials:
References: